IQVIA(US:IQV)2021-10-22 20:44Q3 2021 Financial Performance - Revenue increased to $3391 million, a 217% increase AFx compared to $2786 million in Q3 2020[8,9] - Adjusted EBITDA reached $728 million, up from $604 million in Q3 2020[8,12] - Adjusted Diluted EPS rose to $217, compared to $163 in Q3 2020[8,12] Year-to-Date Performance - Year-to-date revenue reached $10238 million, a 270% increase AFx compared to $8061 million in 2020[9] - Year-to-date Adjusted EBITDA was $2194 million, compared to $1649 million in 2020[12] - Year-to-date Adjusted Diluted EPS was $648, compared to $432 in 2020[12] Segment Revenue Growth - Technology & Analytics Solutions revenue was $1337 million, a 108% increase AFx compared to $1207 million in Q3 2020[9] - Research & Development Solutions revenue was $1853 million, a 324% increase AFx compared to $1400 million in Q3 2020[9] - Contract Sales & Medical Solutions revenue was $201 million, a 123% increase AFx compared to $179 million in Q3 2020[9] Backlog and Bookings - Research & Development Solutions backlog increased by 127% to $244 billion[14] - Last Twelve Months Net New Bookings increased by 173% to $101 billion[14] Full Year 2021 Guidance - Updated revenue guidance is $13775 - $13850 million, representing a 213% - 219% increase[18] - Updated Adjusted EBITDA guidance is $2980 - $3010 million, representing a 250% - 263% increase[18] - Updated Adjusted Diluted EPS guidance is $885 - $895, representing a 379% - 394% increase[18]